Drug Profile
Influenza virus vaccine oral - Vaxcel
Latest Information Update: 24 Oct 2021
Price :
$50
*
At a glance
- Originator Vaxcel [CEASED]
- Developer Southern Research Institute; Vaxcel [CEASED]
- Class Influenza virus vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Influenza virus infections
Most Recent Events
- 30 Jun 1999 Discontinued-I for Influenza virus infections in USA (PO)
- 25 Jun 1998 Zynaxis is now called Vaxcel
- 17 Oct 1995 Secretech is now called Zynaxis